Brought to you by 
Biogen Idec options neurodegenerative technology from Amorfix
30 Jan 2023
Executive Summary
Amorfix Life Sciences (diagnostics and treatments for neurodegenerative diseases) granted Biogen Idec an option to license exclusive worldwide rights to a technology that BI can use to develop and sell treatments for amyotrophic lateral sclerosis (ALS).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec options neurodegenerative technology from Amorfix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice